MannKind's inhaled diabetes treatment wins FDA panel support

04/2/2014 | Reuters

An FDA advisory panel endorsed the approval of MannKind's inhaled insulin therapy Afrezza as a treatment for type 1 and type 2 diabetes. Afrezza could especially benefit type 2 diabetes patients who have difficulty injecting themselves with insulin because of poor eyesight or hand arthritis, as well as patients with extreme fear of needles, the panel said. A final decision is expected by April 15.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC